Virosomes Producing Virus-Like Particles in situ for Dengue Prophylaxis

Vishwas Joshi and colleagues from Seagull BioSolutions in India will develop a vaccine against the dengue virus by engineering a defective version of the measles virus to express dengue virus proteins (a so-called virosome), which can induce protective immunity. There is currently no approved vaccine that protects against dengue infection, which causes disease in 50-100 million people annually, some of which are life threatening. They will test the efficacy of the virosomes to prevent dengue virus infection by using them to vaccinate mice and analyzing immunity upon viral exposure. This grant was selected through India's IKP Knowledge Park and their IKP-GCE program.